Deciphering the role of PIK3CA mutations in tumorigenesis of HER2-positive breast cancer

The Defense Health Agency awarded George Mason University $501,515 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the role of PIK3CA mutations in tumorigenesis of HER2-positive breast cancer. Work is performed in Fairfax, Virginia, with a period of performance through August 31, 2029. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public and to investigate medical solutions for the battlefield, with awards typically ranging from $100,000 to $20 million over three to four years on average. Applications undergo two-tier review—peer evaluation for technical merit and programmatic review assessing technical merit, military relevance, and alignment with program intent—with pre-application coordination required through the Electronic Biomedical Research Application Portal (eBRAP).